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Abstract 
The encapsulation of Glucocorticoids (GCs) into long-circulating liposomes (LCLs) is a proven strategy 
to reduce the side effects of glucocorticoids and improve the treatment of inflammatory diseases, such as 
rheumatoid arthritis (RA). With the aim of supporting the development of GC-loaded LCLs, and 
potentially predict patient response to therapy clinically, we evaluated a direct PET imaging radiolabelling 
approach for preformed GC-LCLs in an animal model of human inflammatory arthritis. 
Methods: A preformed PEGylated liposomal methylprednisolone hemisuccinate (NSSL-MPS) 
nanomedicine was radiolabelled using [89Zr]Zr(oxinate)4 (89Zr-oxine), characterised and tracked in vivo 
using PET imaging in a K/BxN serum-transfer arthritis (STA) mouse model of inflammatory arthritis and 
non-inflamed controls. Histology and joint size measurements were used to confirm inflammation. The 
biodistribution of 89Zr-NSSL-MPS was compared to that of free 89Zr in the same model. A therapeutic 
study using NSSL-MPS using the same time points as the PET/CT imaging was carried out. 
Results: The radiolabelling efficiency of NSSL-MPS with [89Zr]Zr(oxinate)4 was 69 ± 8 %. PET/CT 
imaging of 89Zr-NSSL-MPS showed high uptake (3.6 ± 1.5 % ID; 17.4 ± 9.3 % ID/mL) at inflamed joints, 
with low activity present in non-inflamed joints (0.5 ± 0.1 % ID; 2.7 ± 1.1 % ID/mL). Importantly, a clear 
correlation between joint swelling and high 89Zr-NSSL-MPS uptake was observed, which was not 
observed with free 89Zr. STA mice receiving a therapeutic dose of NSSL-MPS showed a reduction in 
inflammation at the time points used for the PET/CT imaging compared with the control group. 
Conclusions: PET imaging was used for the first time to track a liposomal glucocorticoid, showing high 
uptake at visible and occult inflamed sites and a good correlation with the degree of inflammation. A 
subsequent therapeutic response matching imaging time points in the same model demonstrated the 
potential of this radiolabeling method as a theranostic tool for the prediction of therapeutic response - 
with NSSL-MPS and similar nanomedicines – in the treatment of inflammatory diseases 
Key words: Positron Emission Tomography; Nanomedicine; In vivo Liposome Imaging; Personalised 
Nanomedicine; Rheumatoid Arthritis 
Introduction 
Rheumatoid arthritis (RA) is a chronic, auto- 
immune disease that results in joint inflammation as 
well as bone and cartilage damage. RA affects 
approximately 400,000 people in the UK alone [1], 
with global incidence rates of approximately 1% (75 
million people worldwide) [2]. It is a highly 
debilitating disease; causing pain, stiffness, swelling 
and limited motion to patients, and may lead to 
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disability. RA affects any joint and develops at any 
age, although is most prevalent in women, being 3 
times more likely to suffer from it than men.  
 The treatment of RA and other inflammatory 
diseases often includes the use of glucocorticoids 
(GCs), which are well-established drugs with strong 
anti-inflammatory properties. GCs, however, are also 
notorious for their toxicity and wide range of short- 
and long-term side-effects [3]. These include, in the 
long term: cataracts, high blood sugar/diabetes, 
infections, osteoporosis and bone fractures; and in the 
short term: glaucoma, hypertension and 
psychological effects such as psychosis. 
 A strategy with proven efficacy in reducing the 
toxicity of GCs is encapsulation into long-circulating 
liposomes (LCLs, also known as stealth liposomes). 
LCLs can passively accumulate in inflamed tissues by 
exploiting the leakiness of the vasculature as well as 
inflammatory cell sequestration present in these 
tissues (ELVIS phenomenon: extravasation through 
leaky vasculature and subsequent inflammatory 
cell-mediated sequestration) [4–6]. This may lead to 
preferential accumulation of LCLs at inflamed sites, 
reducing systemic toxicity and improving the 
treatment of inflammatory diseases such as RA [4]. In 
order to understand the in vivo behaviour of LCLs, 
including the level of accumulation at inflamed sites, 
it is important to develop non-invasive imaging 
techniques for visualising, quantifying, and 
monitoring their biodistribution over time. This will 
support the effective selection of the best LCLs for 
clinical translation [7]. In addition, the field of 
nanomedicine is increasingly becoming aware that the 
ELVIS and enhanced permeation and retention (EPR) 
phenomena can be highly variable in humans. For 
example, the uptake of anti-cancer LCLs in solid 
tumours (that rely on the EPR phenomenon) is highly 
heterogeneous in patients, differing not only from 
person-to-person but also from lesion-to-lesion, even 
within the same patient [8–10]. To overcome this 
issue, the concept of ‘personalised nanomedicine’ – in 
which medical imaging is used in a theranostic 
approach to predict the efficacy of the nanomedicinal 
treatment – has been proposed [11]. In the context of 
LCLs, this would involve whole-body in vivo tracking 
of a sub-therapeutic dosage of the liposomal 
nanomedicine. The treatment of a patient can then be 
tailored based on the whole-body biodistribution and 
levels of accumulation of the nanomedicine in 
inflamed tissues [11]. It is expected that 
implementation of this approach will allow selection 
of the best nanomedicine candidates for clinical 
translation, hence optimizing this expensive process. 
In addition, it should improve their therapeutic 
clinical efficacy, by providing a method to pre-select 
only those patients that will truly benefit from the 
nanomedicinal treatment.  
 To support the preclinical and clinical 
development of LCLs as well as personalised 
nanomedicine approaches, we aim to develop simple 
radiolabelling tools to track LCLs in vivo using 
positron emission tomography (PET) [7,12–14]. This 
imaging modality is the most sensitive and 
quantifiable technique available for whole-body 
nanomedicine tracking over time, in both animals and 
humans. With this goal in mind, we recently 
developed a method that allows radiolabelling of 
liposomes without modification [12–14]. By utilising 
radio-ionophore complexes such as [89Zr]Zr(oxinate)4 
(89Zr-oxine) to transport radionuclides across the lipid 
bilayer, we found that chelating groups on the 
incorporated drugs allowed efficient trapping of the 
radionuclides inside the liposomal core for in vivo PET 
imaging. This mechanism allowed us to radiolabel 
and track preformulated PEGylated liposomal 
alendronate (PLA) and DOXIL® in vivo [12,13]. 
In this study we extended this methodology for 
the radiolabelling and in vivo tracking of a PEGylated 
liposomal glucocorticoid (NSSL-MPS). This LCL 
encapsulates the well-established GC 
methylprednisolone hemisuccinate (MPS, Figure 1A) 
and has shown increased efficacy versus 
non-liposomal MPS in several animal models of 
inflammation [5] – particularly in RA [15,16]. In this 
work, NSSL-MPS (Figure 1B) was directly labelled 
using [89Zr]Zr(oxinate)4 (structure in Figure 1C) and 
tracked in vivo in a RA mouse model to assess the 
extent of uptake in inflamed arthritic joints, as well as 
healthy joints, and investigate whether this imaging 
method could be used in a theranostic approach. 
Materials and methods 
All chemical reagents were purchased from 
commercial sources. Water (18.2 MΩ·cm) was 
obtained from an ELGA Purelab Option-Qsystem. IR 
analysis was carried out using a PerkinElmer 
Spectrum 100 FT-IR spectrometer. No-carrier-added 
89Zr (produced at the BV Cyclotron, VU Amsterdam, 
NL) was purchased from PerkinElmer as 
[89Zr]Zr(oxalate)4 in 1 M oxalic acid. Radioactivity in 
samples was measured using a CRC-25R dose 
calibrator (Capintec). iTLC-SG and SA 
chromatography plates were purchased from Agilent, 
UK and scanned using a PerkinElmer Cyclone Plus 
Storage Phosphor Imager. PET/CT imaging was 
performed on a nanoScan in vivo PET/CT preclinical 
imager (Mediso Medical Imaging Systems, Budapest, 
Hungary). Gamma counting was performed using a 
Wallac 1282 CompuGamma γ counter. DOXEBO 
(LC500) was supplied by the Barenholz lab. The 
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human biological samples were sourced ethically and 
their research use was in accord with the terms of the 
informed consents under an Institutional Review 
Board/Ethics Committee (IRB/EC) approved 
protocol.  
Preparation of PEGylated liposomal 
methylprednisolone (NSSL-MPS) 
PEGylated liposomal methylprednisolone 
(NSSL-MPS) was prepared as previously described 
[15,17]. Briefly, lipids (hydrogenated soy-bean 
phosphatidylcholine/cholesterol/PEG-DSPE-2000 of 
56.6:38.1:5 mole %; 3:1:1, w/w) were dissolved in 
ethanol and then were hydrated with 250 mM calcium 
acetate at 65°C, above the phase transition 
temperature. The large multilamellar vesicles formed 
upon lipid hydration were downsised by sequential 
extrusion at 65°C through polycarbonate filters of 
decreasing defined pore size, starting with a 400 nm 
pore size filter and ending with a 50 nm pore size 
filter, under increasing nitrogen pressure (up to 200 
pounds/square inch). Calcium acetate in the external 
liposome medium was replaced by 10% sucrose (w/v) 
by a diafiltration step at 4ºC using a Labscale TFF 
System having a Pellicon XL, 500 K polyethersulfone 
membrane (Millipore Corp., Billerica, Maine, USA). 
The nano-liposomes exhibiting transmembrane 
calcium acetate gradient were remotely-loaded with 
MPS sodium salt as previously described [17]. 
NSSL-MPS radiolabelling with 
[89Zr]Zr(oxinate)4 
[89Zr]Zr(oxinate)4 was synthesised as previously 
reported [18,19]; full details are provided in the 
supplementary information. The radiolabelling of 
NSSL-MPS was based on our previously reported 
method [12]. Briefly, [89Zr]Zr(oxinate)4 was incubated 
with NSSL-MPS liposomes for 30 min at 50 oC with 
regular agitation. The mixture (150 – 200 µL) was left 
to cool to room temperature and then loaded onto a 
G-25 Minitrap size exclusion (SE) column (GE 
Healthcare, pre-washed with 8 mL of saline), followed 
by the addition of saline (300 – 350 µL), to make the 
final volume of sample loaded into the column equal 
to 0.5 mL. The 89Zr-labelled liposomes (89Zr-NSSL- 
MPS) were eluted from the column by the addition of 
saline (750 µL). The eluate and column were 
γ-counted and the liposome labelling efficiency (LE) 
was calculated as: 
%LE = [liposome fraction CPM / (liposome fraction 
CPM + column CPM)] × 100. 
where CPM = counts per minute 
 The in vitro stability of 89Zr-NSSL-MPS was 
evaluated as indicated below by incubation in human 
serum and PBS (1:2 v/v liposome/serum, 0.11 
mg/mL MPS, 0.91 mg/mL lipids) over 48 h at 37 oC 
and room temperature, respectively.  
For PBS stability: At 1 h, 24 h, and 48 h, a 0.25 
mL aliquot of the 89Zr-NSSL-MPS dispersion in PBS 
was added to a 10 mM aqueous solution of DTPA (50 
µL) and left to sit for 5 min. The resulting solution was 
then loaded onto a G-25 Minitrap size exclusion 
column (GE Healthcare, pre-washed with 8 mL of 
saline), followed by the addition of aliquots of saline 
(200 µL). The 89Zr-labelled liposomes (89Zr-NSSL- 
MPS) were eluted from the column by the addition of 
saline (800 µL). The eluate and column were 
γ-counted and the stability was calculated as: 
% Labelled liposome fraction = [liposome fraction 
CPM / (liposome fraction CPM + column CPM)] × 
100. 
where CPM = counts per minute 
For human serum stability: At 1 h, 24 h, and 48 
h, 0.2 mL of the resulting mixture was injected into a 
size exclusion chromatography column (Superose 6 
Increase 10/300 GL column; GE Healthcare, UK) at a 
flow rate of 0.5 mL PBS buffer/min. This method has 
been previously used to efficiently separate liposomes 
from serum proteins and small molecules [12,20,21]. 
Using our system, liposomes elute as a single peak 
between fractions 8 and 11 mL, and serum proteins 
elute between 18 and 25 mL. All fractions were 
γ-counted, and the column was monitored to confirm 
the absence of remaining activity. To measure the 
stability of 89Zr-NSSL-MPS, the following formula 
was used: 
% Labelled liposome fraction = [liposome fractions 
CPM / (liposome fractions CPM + serum protein 
fractions CPM)] × 100 
where CPM = counts per minute 
Arthritis induction and animal monitoring 
Inflammatory arthritis was induced using the 
K/BxN serum transfer arthritis (STA) model [22,23]. 
Briefly, 9-week old female C57Bl/6J mice (n = 5) were 
injected i.p. with arthritogenic serum (150 µL, 50 % 
v/v PBS, obtained from K/BxN transgenic mice) on 
day 0, followed by an additional injection on day 2 
(Figure 2A). Control groups were injected i.p as above 
with non-arthritogenic serum (150 µL, 50 % v/v PBS; 
n = 4) or PBS (150 µL; n = 5). The animals were 
weighed and visual inflammation scores assigned on 
each day post-serum injection, along with caliper 
measurements being performed on the wrists and 
ankles on days 0, 2, 5, 7 & 9 (Figure 2B). Caliper 
measurements were used to calculate joint swelling 
as: 
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Joint size on day X – Joint size on day 0 = Joint 
Swelling on day X 
PET/CT imaging  
Animal imaging studies were ethically reviewed 
and carried out in accordance with the Animals 
(Scientific Procedures) Act 1986 (ASPA) UK Home 
Office regulations governing animal experimentation 
and the GSK Policy on the Care, Welfare and 
Treatment of Animals. All mice were anesthetised 
with isofluorane (2 − 3 %) during all imaging sessions. 
For injection, the lipid concentration of 
89Zr-NSSL-MPS was adjusted to 10 mg/mL by the 
addition of DOXEBO (empty PEGylated liposomes). 
On day 0 (see Figure 2A for schedule) 89Zr-NSSL-MPS 
(1.3 MBq, 100 μL saline, 2 mg/kg MPS dosage, 1 
mg/mouse lipid dose) was injected i.v. into the mice 
(n = 14) at t = 0 h. PET/CT imaging was performed at 
t = 48 h p.i. on day 9 (n = 4, RA; n = 4, PBS) for 60 min 
on a nanoScan in vivo PET/CT preclinical imager 
(Mediso Medical Imaging Systems, Budapest, 
Hungary). All PET/CT data sets were reconstructed 
using a Monte Carlo based full 3D iterative algorithm 
(Tera-Tomo, Mediso Medical Imaging Systems, 
Budapest, Hungary). Decay correction to time of 
injection was applied. CT images were obtained with 
55 kVp tube voltage, 1200 ms exposure time in 360 
projections. All the images were analysed using 
VivoQuant software (inviCRO, USA).  
Ex vivo biodistribution 
Biodistribution studies were carried out in 
accordance with UK Home Office regulations 
governing animal experimentation. Immediately after 
the PET/CT imaging studies (at t = 49 h p.i. on day 9) 
mice (n = 14) were culled by cervical dislocation 
whilst under anaesthesia, and the organs of interest 
were dissected. Each sample was then weighed and 
counted with a γ counter, together with standards 
prepared from a sample of the injected 89Zr-NSSL- 
MPS to obtain percentages of the injected dose per 
mass values (% ID/g) for each organ/tissue. 
Histology 
All joints were fixed in 4 % formalin for one 
week at 4 °C and were processed by UCL IQPath 
(London, UK) for histologic analysis. FFPE organ 
blocks were sliced and stained with hematoxylin & 
eosin. Immunohistochemistry was performed with a 
Discovery XT system (Ventana Medical Systems) 
using the DAB Map detection kit (Ventana #760-124). 
For pre-treatment, CC1 (Ventana #950-124) was used. 
Sections were stained for neutrophil elastase 
(anti-Ly6G), macrophages (anti-F4/80) and blood 
vessels (anti-CD31).  
NSSL-MPS therapy study 
Inflammatory arthritis was induced in female 
9-week old C57Bl/6 mice (n = 9) as described above, 
with visual inflammation scores assigned and mouse 
weights taken on each day post-serum injection 
(Figure 7A-B) and caliper measurements being 
performed on the wrists and ankles on days 0, 2, 5, 7 – 
14 (Figure 7C-D). At day 7 post-serum injection, all 
mice were anesthetised with isofluorane (1.5 – 2%) 
and either NSSL-MPS (100 µL, 25 mg/kg MPS dosage, 
4.7 mg/mouse lipid dose; n = 5) or PBS (100 µL; n = 4) 
were injected i.v. into the mice. Both the visual 
inflammation scores and caliper measurements were 
blinded after injection of the liposomes (day 8 – 14). 
Any joints which did not show signs of inflammatory 
arthritis were excluded from the swelling plots in 
Figure 7 (data is shown in the supplementary Figure 
S1). 
Results  
NSSL-MPS can be radiolabelled with 
[89Zr]Zr(oxinate)4 
 The radiolabelling reaction of NSSL-MPS with 
[89Zr]Zr(oxinate)4 is shown schematically in Figure 
1D. The metastable, neutral and lipophilic [89Zr] 
Zr(oxinate)4 complex passively crosses the lipid 
bilayer of the liposomes releasing the radionuclide 
inside the aqueous liposomal core. The free 89Zr ion is 
then trapped via binding to chelation groups on MPS 
(Figure 1A). IR spectroscopy of a MPS and ZrCl4 
mixture (Figure S2) showed the formation of two 
bands (1550 cm-1 and 1450 cm-1) corresponding to a 
Zr-O bond between Zr4+ and a carboxylate group 
(Zr-OOC), indicating that 89Zr binds via the 
carboxylate on the hemisuccinate moiety. After 30 
min incubation at 50 °C, and subsequent purification 
using a SE column, the labelling efficiency (LE) was 
found to be 69.3 ± 7.7 % (n = 6). No effect on the size 
(hydrodynamic diameter) of NSSL-MPS or its surface 
charge (z-potential) was observed (Figure 1E, Table s1 
in the supplementary information). The 
hydrodynamic diameter of NSSL-MPS was 77 ± 1.4 
nm and 78.8 ± 1.2 nm before and after labelling 
respectively (P = 0.8471, no significance), and the 
z-potential was -5.9 ± 1.1 mV and -3.5 ± 1.8 mV before 
and after the labelling of NSSL-MPS with 
[89Zr]Zr(oxinate)4 (P = 0.5438, no significance). The in 
vitro radiolabelling stability of 89Zr-NSSL-MPS was 
tested by incubation with PBS at room temperature 
and with human serum at 37 oC over 48 h. The 
radiolabelled liposomes were then separated from 
non-liposome associated 89Zr in PBS by passing them 
down a G-25 SE column. 89Zr-NSSL-MPS was 
separated from serum proteins using a SE column on 
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a fast protein liquid chromatography (FPLC) system. 
Figure 1F summarises the stability of 89Zr-NSSL-MPS 
over 48 h. At 1 h incubation, the amount of 89Zr 
associated with NSSL-MPS was 85.0 ± 1.7 % and 86.5 ± 
2.1 % in PBS and serum, respectively. Whilst the 
stability in serum remained unchanged, with 87.0 ± 
0.4 % stability at 48 h, there was a slight decrease for 
89Zr-NSSL-MPS in PBS with 79.4 ± 7.3 % stability at 
48 h. 
 
 
Figure 1. (A) Chemical structure of the glucocorticoid used in this study, methylprednisolone hemisuccinate (MPS). The predicted chelating groups on the drug are 
highlighted in blue. (B) TEM images of the MPS-LCL, NSSL-MPS. (C) Chemical structure of the radio-ionophore complex [89Zr]Zr(oxinate)4. (D) Scheme showing the 
radiolabelling of liposomes using [89Zr]Zr(oxinate)4. (E) Size measurements of NSSL-MPS (left, n.s. = not significant; P = 0.8471) and zeta potential measurements 
(right, n.s.; P = 0.5438) before and after radiolabelling with [89Zr]Zr(oxinate)4. Data represents n = 1, in triplicate. (F) Stability of 89Zr-NSSL-MPS in PBS and serum 
stability (37 ºC) across 48 h (n = 3). All error bars represent mean ± SD. 
 
Figure 2. (A) Experimental schedule used for the induction of inflammatory arthritis in the K/BxN STA mouse model and subsequent PET/CT imaging study; (B) Plot 
of the caliper measurements in each of the wrists and ankles over time. 
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89Zr-NSSL-MPS can be tracked in vivo using 
PET imaging, revealing high uptake into both 
exposed and occult inflamed joints in an 
animal model of human inflammatory arthritis  
After the successful radiolabeling of NSSL-MPS, 
the ability of these liposomes to accumulate at 
arthritic joints was assessed using PET imaging. 
Figure 2A shows the experimental schedule used. 
Inflammatory arthritis was induced in healthy female 
C57Bl/6J mice (n = 5) by intraperitoneal injection of 
K/BxN serum on days 0 and 2, whereas control 
groups were either injected with non-arthritogenic 
(normal) mouse serum (n = 4) or PBS (n = 5). The size 
of the wrists and joints of each animal were monitored 
to track the progress of the disease. Figure 2B shows 
the size for each of the wrists and ankles over time for 
all animals, demonstrating that only joints of the STA 
mice group showed an increase. This model induces 
an asymmetric pattern of inflammation, with more 
inflamed joints in the right hand side of the animal 
(7/10) than in the left side (5/10), and more 
inflammation in ankles (8/10), than in wrists (4/10).  
On day 7 post-arthritic serum or controls 
(PBS/normal serum) injection, 89Zr-NSSL-MPS (1.3 
MBq, 100 µL saline, 2 mg/kg MPS dosage, 1 
mg/mouse lipid) was injected intravenously into all 
mice. This was followed by PET imaging 48 h later 
(day 9) of four mice from the STA and PBS groups. 
This imaging time point was chosen to allow the 
liposomes to be in circulation during the peak of 
inflammation, which occurs at days 8 – 9 post 
induction,[24] and taking into account that the 
circulation half-life of NSSL-MPS liposomes is t1/2 = 34 
h [15]. This long circulation half-life is consistent with 
preliminary PET imaging studies in healthy mice 
(Figure S4). Ex vivo biodistribution was carried out on 
all mice after the imaging sessions. PET/CT imaging 
of the STA mice (Figure 3A) showed high 
89Zr-NSSL-MPS uptake at inflamed joints (3.6 ± 1.5 % 
ID; 17.4 ± 9.3 % ID/mL, n = 12 combining ankles and 
wrists, Figure 3B). In contrast, control groups lacking 
joint inflammation showed low uptake (0.5 ± 0.1 % ID, 
n = 36; 2.7 ± 1.1 % ID/mL, n = 16). 89Zr-NSSL-MPS 
uptake into non-target organs was similar across all 
groups, with high uptake in spleen (53.6 ± 8.8 % ID/g, 
n = 14) and liver (30.9 ± 4.7% ID/g, n = 14) (Figure 
3C). Furthermore, plotting the joint-to-organ (heart, 
muscle, liver and spleen) ratio of inflamed and 
non-inflamed joints (non-inflamed defined as joints 
with swelling <0.5 mm on day 9) showed a 
significantly higher ratio for inflamed joints (Figure 
3D).  
 
Interestingly, 89Zr-NSSL-MPS PET detected 
unexpected high levels of uptake in joints that were 
not detected visually. Particularly, very high 
accumulation was detected in the right knee of two 
mice from the disease group (45.0 ± 1.6 % ID/mL; n = 
2, Figure 4A), as well as in two hind paw digital joints 
(13.2 ± 2.4 % ID/mL; n = 2, Figure 4A). These levels of 
uptake are significantly higher compared to 
non-inflamed knees (19.4 ± 3.1 % ID/mL; n = 14) and 
hind paw digital joints (2.5 ± 1.5 %ID/mL; n = 8). 
Histological confirmation of inflammation was 
obtained for the knees (Figure 4), showing 
characteristic high levels of neutrophil infiltration and 
increased angiogenesis (Figure 4B-C) [24].  
PET imaging and ex vivo biodistribution studies 
demonstrate a correlation between 89Zr- 
NSSL-MPS uptake levels in joints and 
inflammation  
A clear relationship between increased joint 
swelling/inflammation and high 89Zr-NSSL-MPS 
uptake was observed (Figure 5A-C). Joint swelling 
(defined as those >0.5 mm) was only observed in the 
disease group, which showed high 89Zr-NSSL-MPS 
uptake of 2.0 ± 0.5 % ID (n = 4) in wrists and 4.4 ± 1.0 
% ID (n = 8) in ankles compared to non-inflamed 
joints which had uptake of 0.4 ± 0.1 % ID (n = 24) and 
0.6 ± 0.1 % ID (n = 20) for wrists and ankles, 
respectively. The correlation is also evident when 
comparing the data from both joint swelling 
measurements and visual inflammation scores with 
the in vivo uptake of 89Zr-NSSL-MPS based on PET 
imaging quantification, and ex vivo biodistribution 
data (Figure 5D-G, all data from day 9 post serum 
injection).  
The biodistribution of unchelated 89Zr and its 
uptake in inflamed joints is significantly 
different to 89Zr-NSSL-MPS 
 A concern from the 89Zr-NSSL-MPS imaging 
study (vide supra) was the contribution of any 
potential unchelated 89Zr in the uptake into inflamed 
tissues. To evaluate this we injected mice (n = 2) with 
STA on day 7 post serum injection with neutralised 
[89Zr]ZrCl4 (see supplementary information for 
experimental details), performing ex vivo 
biodistribution 48 h p.i. (day 9). The biodistribution of 
[89Zr]ZrCl4 demonstrated a distinct difference in 
accumulation from 89Zr-NSSL-MPS, characterised by 
high bone uptake (33.0 ± 4.5 % ID/g) and low uptake 
(<10 % ID/g) in all other organs – including the liver 
and spleen (Figure 6A). Additionally, the % ID of 
[89Zr]ZrCl4 in the shoulders and femur of STA mice 
was over double compared with 89Zr-NSSL-MPS 
(Figure 6B) – with the same % ID found for the 
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labelled liposomes in the control serum and PBS 
groups. A further distinction between the ‘free 89Zr’ 
and the labelled liposomes could be made when 
plotting %ID in the joints vs. joints swelling (Figure 
6C). Whereas liposomal uptake correlates with joint 
swelling (vide supra), the uptake of [89Zr]ZrCl4 was 
consistent over increasing joint swelling. 
Furthermore, the % ID in inflamed joints was 
consistently lower for [89Zr]ZrCl4 compared to 
89Zr-NSSL-MPS; with 1.0 ± 0.0 % ID and 2.0 ± 0.5 % ID 
respectively for wrists, and 2.1 ± 0.1 % ID and 4.4 ± 1.0 
% ID respectively for ankles. 
Treatment with NSSL-MPS shows anti- 
inflammatory effects in the K/BxN serum- 
transfer arthritis (STA) mouse model of 
human inflammatory arthritis 
Having made the correlation between 
89Zr-NSSL-MPS uptake levels and inflammation in 
joints in arthritic mice, the therapeutic efficacy of 
NSSL-MPS was tested in the same STA model. Figure 
7A shows the experimental schedule used: STA was 
induced in healthy female C57Bl/6J mice (n = 9). On 
day 7 post-serum injection, a therapeutic dose of 
NSSL-MPS (25 mg/kg) was administered (n = 5), 
whereas a control group was injected with PBS (n = 4). 
No adverse effects were seen with either group, based 
on the lack of weight change (Figure 7B). A clear 
reduction in the total visual inflammation score was 
observed for the NSSL-MPS-treated group compared 
with the PBS group between days 7 – 11 (Figure 7C). 
The anti-inflammatory effect of NSSL-MPS was more 
accurately quantified by measuring the joint swelling 
in the wrists and ankles for both groups (Figure 7D-E; 
top). In particular, when directly comparing the 
swelling on day 9 (same timepoint as the PET 
imaging/biodistribution studies) and day 7 
(NSSL-MPS administration), a significantly higher 
reduction in swelling was observed for the NSSL-MPS 
treated group (0.8 ± 0.1 mm and 0.5 ± 0.1 mm for 
wrists and ankles respectively) (Figure 7D-E; bottom). 
In contrast, swelling either plateaued (0.03 ± 0.10 mm 
swelling reduction for wrists) or even increased (-0.2 ± 
0.1 mm swelling increase for ankles) in the control 
PBS group (Figure 7D-E; bottom). As expected, the 
single dose treatment is temporary, as inflammation 
in all cases resumes with an increase in both 
inflammation score and joints swelling observed 
between from day 10 – 11 (3 – 4 days after treatment). 
 
 
Figure 3. (A) PET/CT maximum intensity projections of C57Bl/6J mice with (top row) and without (bottom row) serum induced inflammatory arthritis. Swelling in 
the joints of the arthritic mice is clearly demonstrated by liposomal uptake in the wrists and ankles (orange arrows). (B) Uptake of 89Zr-NSSL-MPS in wrists, ankles 
and knees of mice injected with either arthritic serum or PBS based on image quantification (% ID/mL, left graph; % ID/mL = percentage of the total injected dose per 
mL of tissue) and ex vivo biodistribution (% ID, right graph). (C) Ex vivo biodistribution at 48 h p.i. of 89Zr-NSSL-MPS. (D) Joint-to-organ ratio for heart, muscle (left 
graph), liver and spleen (right graph) for inflamed and non-inflamed joints. Inflammed joints are defined as those with swelling >0.5 mm. **** = P <0.0001; All error 
bars represent mean ± SD. 
Theranostics 2020, Vol. 10, Issue 9 
 
 
http://www.thno.org 
3874 
 
Figure 4. (A) PET/CT MIP of C57Bl/6J mice with suspected inflamed right knees (Knee 1 and Knee 2) and hind paw digit uptake. B) H&E and immunohistochemistry 
showing increased vascularisation (anti-CD31) and neutrophil infiltration (anti-Ly6G) and staining for macrophages (F4/80) for Knee 1 and (C) Knee 2. For the left 
panels magnification is 4x with the black bar denoting 500 µm; for the right panels magnification is 30x with the black bar denoting 100 µm. 
 
 
Figure 5. (A) Plot of %ID of 89Zr-NSSL-MPS versus swelling of wrists, (B) versus swelling of ankles, and (C) versus visual inflammation scores (all joints from all 
groups) at day 9 post serum injection; (D-G) Heatmaps showing (D) joint swelling, (E) visual inflammation scores, (F) 89Zr-NSSL-MPS uptake (%ID) from ex-vivo 
biodistribution and (G) image-quantified uptake (%ID/mL) (G) for all mice at day 9. 
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Figure 6. (A) Ex vivo biodistribution of unchelated 89Zr in STA mice 48 h p.i. (B) Uptake (% ID) of 89Zr-NSSL-MPS in the femur and shoulders of RA and control mice 
(blue dots, red squares and green triangles) and uptake (% ID) of unchelated 89Zr NSSL-MPS in the femur and shoulders of STA mice (purple diamonds). (C) Plot of 
% ID of 89Zr-NSSL-MPS and unchelated 89Zr versus swelling of wrists and (D) versus swelling of ankles at day 9 post serum injection. All error bars represent mean 
± SD. 
 
Figure 7. (A) Experimental schedule used for the induction of inflammatory arthritis and subsequent NSSL-MPS therapy study. (B) Animal weights over time for the 
NSSL-MPS and PBS treated mice; for reference day 7 (day of administration) is shown by the dotted line. (C) Plot of the total visual inflammation scores over time of 
the NSSL-MPS (n = 5) and PBS (n = 4) treated mice; for reference day 7 is shown by the dotted line. (D) Plot of the wrist swelling of over time for both treament 
groups (top) and a comparison of the reduction in wrist swelling between days 7 and 9 for both treatment groups (bottom). (E) Plot of the ankle swelling of over time 
for both treament groups (top) and a comparison of the reduction in ankle swelling between days 7 and 9 for both treament groups. Any joints which did not show 
signs of inflamation were excluded from the swelling plots. All error bars represent mean ± SD. *** P = 0.0001; **** P = <0.0001. 
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Discussion 
The rationale behind the radiolabelling and in 
vivo tracking of LCLs such as NSSL-MPS is two-fold: i) 
to aid in their pre-clinical development and clinical 
translation, and ii) as potential theranostic agents to 
support the clinical usage of personalised medicine. 
Hence, the radiolabelling of a liposomal 
nanomedicine should ideally not involve any 
modification of the original structure of the LCL. In 
addition, it must facilitate the stable incorporation of a 
radionuclide with a radioactive half-life that matches 
that of the LCL in vivo, due to their long circulating 
properties. Generally, these properties are 
accomplished via the use of chelators; either attached 
to the lipid surface or encapsulated inside the 
liposomal core. However, even small changes in these 
modifications, such as the PEG chain length between 
the chelator and lipid bilayer, can lead to changes in 
the pharmacokinetics and biodistribution [21]. 
Furthermore, studies comparing surface labelling and 
the internal trapping of radionuclides using chelators 
have shown differences in tissue distribution [7,25,26]. 
 89Zr (t1/2 = 78.4 h) was chosen among other 
long-lived positron-emitting radionuclides such as 
64Cu (t1/2 = 12.7 h) as it allows in vivo tracking over the 
circulation half-life of LCLs (t1/2 of NSSL-MPS = 33 h). 
In addition, unlike 64Cu that shares biodistribution 
and excretion pathways with liposomes and other 
nanomedicines (i.e. liver), the biodistribution/ 
excretion pathways of 89Zr in mice is significantly 
different. In particular, free 89Zr shows mostly bone 
uptake and no liver accumulation. This facilitates the 
interpretation of PET imaging studies with 
nanomedicines and other long-circulating drugs such 
as antibodies; particularly at late time points when 
excretion is more likely [7]. Thus, we believe these two 
aspects support the use of 89Zr over 64Cu for the 
tracking of liposomes and other nanomedicines in 
vivo. Our radiolabelling method is chelator-free and 
requires no chemical modification of the liposomal 
formulation [12]. [89Zr]Zr(oxinate)4 is used to 
passively transport the radionuclide inside the 
liposomal core. Once inside, we take advantage of the 
chelating groups often present on the encapsulated 
and highly concentrated drug cargo (Figure 1A) to 
bind to the radiometal and trap it stably. Due to this 
mechanism, the labelling efficiency and stability using 
this method is inherently limited by the interaction 
between the drug and the radiometal. Using IR we 
show that, in the case of MPS, zirconium binding 
occurs through the carboxylate present on the 
hemisuccinate group (Figure S2). As 89Zr will likely be 
in the 4+ oxidation state, coupled with the high 
concentration of MPS within the liposome core, it is 
possible that 89Zr binds to MPS as a Zr(MPS)4 
complex. The %LE of NSSL-MPS was found to be 69.3 
± 7.7 % with a serum stability of 87.0 ± 0.4 % after 48 h, 
which is slightly lower than preceding work using 
this labelling method. For example, [89Zr]Zr(oxinate)4 
radiolabels PEGylated liposomal alendronate (PLA) 
with >95 % LE, and >95 % serum stability after 72 h. 
However, when labelling liposomal doxorubicin 
(DOXIL) lower %LE (50.6 ± 5.3 %) and stability (80% 
after 72 h) was observed indicating an expected less 
favourable radiometal-drug interaction compared to 
that with alendronate [12]. Additionally, we observed 
a sudden loss of activity from 89Zr-NSSL-MPS (ca. 15 
%) after just 1 h incubation in serum and PBS, 
followed by minimal losses over the following 48 h. 
We believe this indicates that a small amount of 89Zr is 
not internalised during labelling and is likely present 
in the phospholipid bilayer, which allows it to be 
more easily trans-chelated by serum proteins or 
DTPA (used in PBS stability). Thus, the %LE of 69.3 ± 
7.7 % calculated directly after synthesis and 
purification, is likely an overestimation, and supports 
incubation with DTPA at 37 ºC for the purification 
step. Abou et al. previously showed that 89Zr could 
bind directly to the lipid phosphate head groups on 
liposomes. However, this interaction was shown to be 
weak, contributing to low stability in both serum and 
in vivo [27]. Thus, it is likely that the small amount of 
weakly bound 89Zr found in our studies is associated 
with the phospholipid phosphate groups. Several 
other GCs that have been encapsulated in LCLs for 
the treatment in inflammation and cancer are shown 
in supplementary Figure S3. Based on our 
observations using PLA we believe that the phosphate 
analogues of prednisolone, dexamethasone and 
budesonide may allow higher radiolabelling yields 
and stability when radiolabelled with [89Zr] 
Zr(oxinate)4. Indeed, inorganic nanoparticles based on 
a zirconium betamethasone phosphate complex have 
been previously reported – indicating stability for this 
Zr-GC interaction [28]. 
 The ability of PET imaging to measure the 
uptake levels of 89Zr-NSSL-MPS in a relevant disease 
model was evaluated in the K/BxN serum transfer 
model of human inflammatory arthritis such as RA. 
This model has been shown to represent several of the 
hallmarks of RA [23], and was chosen over others (e.g. 
collagen induced arthritis, CIA) for its ability to 
replicate the effector phase of the disease in several 
strains of mice, and its rapid and transient effect. The 
K/BxN serum introduces autoantibodies against 
glucose-6-phosphate isomerase (GPI) into healthy 
mice (here C57Bl/6), a commonly found antibody in 
RA patients. This results in the activation of innate 
immune cells such as neutrophils, and rapid 
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induction of a transient inflammatory arthritis in fully 
immunocompetent mice. We were successfully able to 
track 89Zr-NSSL-MPS to inflamed joints as well as the 
distribution in healthy control mice. Uptake of 
89Zr-NSSL-MPS was significantly higher in joints with 
inflammation (3.6 ± 1.5 % ID; 17.4 ± 9.3 % ID/mL) 
compared to those in control mice where no signs of 
inflammation were observed (0.5 ± 0.1 % ID, n = 36 & 
2.7 ± 1.1 % ID/mL, n = 16). 89Zr-NSSL-MPS 
biodistribution showed common patterns with other 
LCLs, with major uptake in the organs of the 
mononuclear phagocytic system, mainly spleen and 
liver. Additionally, low levels of bone uptake were 
observed across all groups, primarily in shoulders, 
knees and spine. We believe this is due to release of 
small amounts of ‘free 89Zr’ from the LCLs which is 
known to bind to bone minerals [29], although it is not 
clear whether this release is occurring whilst 
circulating in the blood stream, or after uptake in 
tissues. Since LCLs are well known to be taken up by 
macrophages [30], we believe the latter is the most 
likely mechanism. Additionally, uptake of 89Zr-NSSL- 
MPS in the bone marrow, a component of the 
mononuclear phagocytic system, cannot be ruled out 
but was not measured. Through both PET image 
quantification and ex vivo biodistribution studies we 
have shown that there is a clear correlation between 
increased 89Zr-NSSL-MPS uptake and increased 
swelling in joints, indicating that 89Zr-NSSL-MPS 
uptake also correlates with the extent of inflammation 
in affected joints.  
We have also demonstrated that the 
biodistribution of ‘free 89Zr’ (as the chloride salt) is 
distinct from that of 89Zr-NSSL-MPS, with high bone 
uptake (33.0 ± 4.6 % ID/g) and low spleen and liver 
uptake (3.5 ± 1.3 & 6.0 ± 1.7 % ID/g respectively), 
which is more than double than with 89Zr-NSSL-MPS. 
It is important to highlight these differences, as 
increased uptake of ‘free 89Zr’ in the form of 
[89Zr]Zr(oxalate)4 in arthritic joints has been 
previously reported [31]. Hence, we also wanted to 
show that ‘free 89Zr’ released from liposomes did not 
preferentially accumulate in inflamed tissues. Indeed, 
we found that there was no correlation when 
comparing uptake of ‘free 89Zr’ versus joint swelling. 
Therefore, in this case we believe that the uptake of 
‘free 89Zr’ in inflamed joints is likely due to the 
binding of ‘free 89Zr’ to the bone in joints. 
Additionally, these results indicate that 89Zr-NSSL- 
MPS uptake is predominantly from the accumulation 
of the liposomes in inflamed joints and not the result 
of 89Zr being released from liposomes in circulation. 
Despite this, the potential issue of misinterpretation of 
images due to the bone uptake of 89Zr for imaging 
liposomes in arthritic joints should not be 
downplayed.  
As shown in Figure 3B, the uptake of 
89Zr-NSSL-MPS in the knees of two mice (ca. 4 % ID, 
45 % ID/mL) was over double that of controls (ca. 1 % 
ID, 20 % ID/mL) indicating the potential presence of 
inflammation. Histology showed the knees were 
indeed arthritic, highlighting the value of this imaging 
approach to detect and treat occult sites of 
inflammation. Whilst the distinction between 
inflamed and non-inflamed knees was possible using 
the PET/CT images, in cases where the extent of 
inflammation in the knee is reduced the elucidation 
between ‘free 89Zr’ and liposomal 89Zr uptake may 
become more difficult. 
After establishing the uptake of NSSL-MPS in 
arthritic joints using PET imaging, we performed a 
follow up study to assess the therapeutic efficacy of 
NSSL-MPS at the same time points of imaging. A clear 
anti-inflammatory effect was observed from a single 
dose of NSSL-MPS. This data matches previous work 
with NSSL-MPS in the adjuvant-induced arthritis 
(AIA) rat model [15,16]. Direct comparisons of the 
overall therapeutic response should be made with 
caution however; firstly due to the use of a different 
animal model and secondly due a difference in 
treatment regime. Avnir et al. administered two doses 
of NSSL-MPS (10 mg/kg) five days apart and showed 
a sustained reduction in RA for up to 6 days after 
administration of the initial dose [15]. In contrast, we 
administered a single 25 mg/kg dose of NSSL-MPS 
with a peak in reduction of inflammation at 3 – 4 days 
after which swelling and inflammation gradually 
began to increase again (Figure 7). 
Similarly to this study, Metselaar et al. 
radiolabelled a therapeutic dose (10 mg/kg) of 
liposomal prednisolone phosphate (LCL-PLP) 
containing the 111In chelator DTPA and imaged in AIA 
rats [32]. Scintigraphic whole body images showed 
gradual uptake in inflamed paws, peaking at 48 h 
with ex vivo biodistribution at the same point 
demonstrating higher uptake in the paws of AIA rats 
compared to healthy controls. Overall paw uptake 
was <1 % ID/g across all groups, which may seem 
low compared to the values obtained in this study, 
but consistent with the larger animals used. Similar to 
our study (Figure 7D-E), a maximal therapeutic effect 
was reached at 48 – 72 h post injection of LCL-PLP. 
 As previously discussed, our radiolabelling 
method has been successful with a variety of different 
liposomal nanomedicines. Hence, we believe that our 
PET tracking method could be used to predict the 
efficacy of other liposomal GCs (vide supra), and in 
other diseases. In particular, LCL-PLP has previously 
been investigated clinically for the treatment of 
atherosclerosis [33]. Van der Valk et al. confirmed 
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uptake in the atherosclerotic plaques using an 
anti-PEG antibody which showed co-localisation with 
macrophages in the lesions. Despite this, patients 
receiving the LCL treatment showed no reduction in 
inflammation. The tracking of such LCLs using PET 
may provide a non-invasive, quantitative way of 
assessing liposomal uptake in areas of inflammation, 
for the prediction of treatment. This approach has 
recently been used in the clinic with cancer patients. 
In a major milestone in the clinical application of 
personalised nanomedicine, Lee et al. administered 
HER2-targeted DOXIL (MM-302), radiolabelled with 
64Cu, into breast cancer patients [10]. Image 
quantification using PET images allowed the 
classification of patients into two groups based on 
their lowest lesion uptake. From this a correlation 
between high 64Cu-MM-302 uptake and better 
treatment response was found.  
 Finally, there are some limitations in our study 
worth discussing. First, we believe our PET and 
therapy studies provide substantial evidence of the 
effectiveness of the radiolabelling method and 
preferential accumulation of NSSL-MPS in inflamed 
joints, resulting in an anti-inflammatory effect. 
However, we were not able to measure MPS 
concentration in these joints ex vivo. Doing so would 
provide a more direct link between the PET signal and 
therapeutic efficacy. Secondly, we were not able to 
perform combined longitudinal imaging/therapy 
studies. This would allow us to directly link PET 
signal with the development of inflammation and 
ultimately therapeutic efficacy in individual joints, 
providing a more direct proof that PET imaging with 
89Zr-NSSL-MPS can be predictive of NSSL-MPS 
therapy. To address these limitations future studies 
should include longitudinal PET imaging/therapeutic 
studies, as well as ex vivo analysis of MPS 
concentration in individual joints. Lastly, there are 
general concerns about the radiation safety of 
radiolabelled compounds such as 89Zr-NSSL-MPS. 
However, our previous calculations with similar 
89Zr-liposomes estimated human radiation doses of 
0.9 ± 0.2 mSv/MBq, which is within the range of those 
reported for 89Zr-antibodies in human studies [12]. 
For these reasons, we believe that imaging 
89Zr-NSSL-MPS has potential for clinical translation, 
although more detailed imaging studies will have to 
be carried out in order to accurately calculate the 
radiation dose in humans. 
Conclusions 
We have shown that preformed glucocorticoid- 
loaded liposomes can be radiolabelled with 
[89Zr]Zr(oxinate)4. By using this method, PET imaging 
was used for the first time to study the biodistribution 
of a glucocorticoid-loaded liposome, which 
demonstrated high uptake at visible and occult 
inflamed sites in an RA model. A follow-up therapy 
demonstrated a clear reduction in inflammation in 
mice treated with NSSL-MPS. We believe our 
liposome labelling technique followed by in vivo PET 
tracking will be a useful tool in the preclinical and 
clinical development of anti-inflammatory liposomal 
nanomedicines of this type, and could be used to 
predict the therapeutic response to NSSL-MPS 
treatment, as well as with similar nanomedicines, in 
patients with various inflammatory diseases. 
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